Shots:

• Moleculin collaborated with Emory University to conduct P-I trial for WP1066 to treat recurrent or refractory malignant brain tumors in pediatric patients
• The trial will be conducted at Aflac Cancer & Blood Disorders Center at Children's Healthcare of Atlanta- with its expected recruitment in H2’19
• WP1066 is an immuno-stimulating STAT3 inhibitor will be evaluated in P-I and is developed for targeting brain tumors- pancreatic cancer and AML

Click here to read full press release/ article | Ref: Moleculin | Image: Twitter